Apogee Therapeutics to Host Conference Call to Report Interim Results from the Phase 1 Healthy Volunteer Trial for APG990 and Provide Combination Strategy Update on March 3, 2025

Rhea-AI Summary

Apogee Therapeutics (Nasdaq: APGE) has scheduled a conference call and webcast for March 3, 2025, at 8:30 a.m. ET to present interim results from its Phase 1 healthy volunteer trial of APG990. The clinical-stage biotechnology company, which focuses on developing novel biologics for inflammatory and immunology (I&I) conditions, will also discuss combination strategy plans for APG777 + APG990.

The company's therapeutic pipeline targets major I&I markets, including:

• Atopic dermatitis (AD)
• Asthma
• Eosinophilic esophagitis (EoE)
• Chronic obstructive pulmonary disease (COPD)

The live webcast will be accessible through the company's investor relations website, with a replay available after the call.

Webcast to be held Monday, March 3rd at 8:30 a.m. ET

SAN FRANCISCO and BOSTON, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD) and other I&I indications, today announced it will report interim results from the Phase 1 APG990 healthy volunteer trial on Monday, March 3, 2025. Following the announcement, the Company will host a conference call and webcast at 8:30am ET to discuss the results and plans for its combination approach for APG777 + APG990.

Webcast Details
Apogee Therapeutics’ live webcast of the APG990 interim Phase 1 results will begin on Monday, March 3^rd at 8:30 a.m. ET. The live webcast can be accessed via this link or the Investors section on the Company’s website at https://investors.apogeetherapeutics.com/news-events/events. A replay of the webcast will be available following the call.

About Apogee
Apogee Therapeutics is a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest I&I markets, including for the treatment of AD, asthma, EoE, COPD and other I&I indications. Apogee’s antibody programs are designed to overcome limitations of existing therapies by targeting well-established mechanisms of action and incorporating advanced antibody engineering to optimize half-life and other properties. APG777, the company’s most advanced program, is being initially developed for the treatment of AD, which is the largest and one of the least penetrated I&I markets. With four validated targets in its portfolio, Apogee is seeking to achieve best-in-class efficacy and dosing through monotherapies and combinations of its novel antibodies. Based on a broad pipeline and depth of expertise, the company believes it can deliver value and meaningful benefit to patients underserved by today’s standard of care. For more information, please visit https://apogeetherapeutics.com.

Investor Contact:
Noel Kurdi
VP, Investor Relations
Apogee Therapeutics, Inc.
noel.kurdi@apogeetherapeutics.com

Media Contact:
Dan Budwick
1AB Media
dan@1abmedia.com

FAQ

When will Apogee Therapeutics (APGE) report Phase 1 interim results for APG990?

Apogee Therapeutics will report interim results from the Phase 1 APG990 healthy volunteer trial on March 3, 2025, during a conference call at 8:30 a.m. ET.

What therapeutic areas does APGE's pipeline target?

APGE focuses on inflammatory and immunology conditions including atopic dermatitis, asthma, eosinophilic esophagitis, and chronic obstructive pulmonary disease (COPD).

What will be discussed in APGE's March 3rd conference call?

The call will cover interim results from the Phase 1 APG990 healthy volunteer trial and plans for the combination approach of APG777 + APG990.

How can investors access APGE's March 3rd webcast?

Investors can access the live webcast through the Investors section of Apogee Therapeutics' website at investors.apogeetherapeutics.com/news-events/events.